|
| Perspective From Industry Leaders |
|
|
| Pfizer’s Dolsten Plans Exit, Ushering In R&D Transition | VC Insights On Future Tech And Future Leaders |
|
Chief scientific officer and president of Pfizer Research & Development Mikael Dolsten will depart the company... |
“I'm a strong believer in creating the right mix between young ambitious people and pairing them up... |
| Licensing & Collaboration Agreements |
|
|
| Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens | Deal Volume Up, Value Down During The First Half |
|
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more. |
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024... |
| Next Gen R&D |
|
|
| Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’ | Floreo CEO Champions FDA Path For Autism VR Therapy |
|
CEO Ken Mariash and scientific co-founder Giacomo Koch discuss plans for a Phase 3 trial in 2025 supporting... |
Vijay Ravindran, founder of autism therapy digital therapeutic firm Floreo, spoke to Medtech Insight about... |
| Clinical Trials |
|
|
| Tackling The Challenge Of Malaria Clinical Trials In Africa | Will US Clinical Study Diversity Guidance Cloud Chinese Firms’ Prospects For Going Global? |
|
Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat... |
The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global... |
|
|
|
Citeline Contact Poornachandra Tejasvi .K, 
|
IPA Contact Name: Hari Pranav K |